image description

Category: LupusTrials.org

Promise of Additional Lupus Therapies Highlighted at ACR 2021 Annual Meeting

November 9, 2021 Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2021, November 3-9. Bringing you the most relevant news for our lupus community, following are summaries of key research presented at the meeting: New Data on Approved Lupus Treatments […] Read More

Two New Drugs Receive FDA Approval

May 1, 2021 “This is a historic moment in lupus with two new drug approvals for lupus nephritis just over a month,” enthused Kenneth M. Farber, LRA President and CEO. The LRA is excited to share that the U.S. Food and Drug Administration (FDA) has approved the use of voclosporin (Lupkynis™) as the first oral […] Read More

A “Call to Arms” for the Lupus Community

August 18, 2021 Many lupus patients are at risk for COVID-19 infection because of treatment with corticosteroids and other immunosuppressive medications and will be eligible for booster vaccination. However, there are large gaps in our understanding of who will benefit from the booster vaccines, what strategies will improve response to the vaccine and the best […] Read More

Two Studies Show COVID-19 Vaccines are Well-Tolerated Among Lupus Patients

August 12, 2021 In two recent studies, researchers found that the four COVID-19 vaccines are well-tolerated in lupus patients. Given that the Moderna and Pfizer vaccines are the first mRNA vaccines currently authorized for the emergency use in people, lupus researchers have since worked to answer questions specifically about potential side effects and whether these […] Read More

Important Message from CEO Kenneth Farber: U.S. FDA Approves New Lupus Treatment

August 2, 2021 Dear Friend of the Lupus Research Alliance, As we reported this morning, the lupus community has much to celebrate with the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (brand name, Saphnelo™). As a first-in-class and only new treatment for systemic lupus erythematosus in a decade, this approval marks a major […] Read More

Promising New Lupus Treatments Highlighted ACR Annual Meeting

Results of clinical trials testing potential lupus treatments were highlighted at the American College of Rheumatology’s annual meeting ACR Convergence 2020. These studies include phase I trials, which test for side effects and a safe dosage; larger phase II trials, which test for effectiveness and further gauge safety; and large phase III trials, which confirm […] Read More

LRA Highlights Full Continuum of Lupus Research at ACR Convergence 2020

30+ presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from three clinical studies conducted in part by LRA-affiliate Lupus Therapeutics (LT) through its trials network 10 lupus presentations by the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE) NEW YORK, NY, […] Read More

LRA Congratulates Equillium on Positive Results of Study of Potential New Lupus Treatment

March 30, 2021 Equillium, Inc. announced positive topline data from the phase 1b EQUALISE study in patients with systemic lupus erythematosus (SLE).  This study suggests that itolizumab, a monoclonal antibody selectively targeting the CD6-ALCAM pathway, was safe and well tolerated among people with SLE. [Source: Equillium, Inc. Press Release 3.30.21] The EQUALISE study is evaluating […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates